FindTrial
Sign In

Benefits of peppermint oil in upper digestive endoscopies

Use of L-menthol solution as an esophageal antispasmodic in Upper Digestive Endoscopy: pilot project

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-7tgfwmk
Enrollment
Unknown
Registered
2021-05-29
Start date
2021-08-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal motility disorders

Interventions

The study is aimed to compare the efficacy and safety of L-menthol vs scopolamine as an esophageal antispasmodic. Scopolamine is the gold standard currently used, so it will be administered in the con
D02.033.415.510.500.605, D02.455.426.392
D02.092.877.310 D02.145.074.722.822.200

Sponsors

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Lead Sponsor
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18 and under 65;Signed consent form; No known esophageal pathologies; Undergoing diagnostic EDA under conscious sedation

Exclusion criteria

Exclusion criteria: Under 18 or over 65 years old; Refusal to sign the consent form; previously known esophageal pathologies; Undergoing therapeutic examination; Examination performed without sedation or under general anesthesia; Need for the use of scopolamine during the performance of the diagnostic examination before the evaluation for the study

Design outcomes

Primary

MeasureTime frame
It is expected to find a reduction in the number of esophageal contractions after the administration of L-menthol and scopolamine. This outcome will be verified through the count of esophageal contractions that occurred during the period of one minute after the use of L-menthol or scopolamine. The digestive endoscopy will be filmed and an evaluator will perform the count.—

Secondary

MeasureTime frame
It is expected to find a smaller number of adverse effects due to the use of L-menthol compared to scopolamine. Since tachycardia is the main adverse effect of scopolamine, patients' heart rate will be measured before, during, and after the application of L-menthol or scopolamine. One of the advantages of L-menthol is believed to be its only local action. Therefore, a comparison will be made between the participants' heart rates.—

Countries

Brazil

Contacts

Public ContactEpifanio Junior
epifaniosmjr@gmail.com+55 84 996099459

Outcome results

None listed

Source: REBEC (via WHO ICTRP)